Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis
Open Access
- 11 January 2010
- journal article
- research article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 207 (1), 85-100
- https://doi.org/10.1084/jem.20091309
Abstract
Members of the transforming growth factor beta (TGF-beta) family have been genetically linked to vascular formation during embryogenesis. However, contradictory studies about the role of TGF-beta and other family members with reported vascular functions, such as bone morphogenetic protein (BMP) 9, in physiological and pathological angiogenesis make the need for mechanistic studies apparent. We demonstrate, by genetic and pharmacological means, that the TGF-beta and BMP9 receptor activin receptor-like kinase (ALK) 1 represents a new therapeutic target for tumor angiogenesis. Diminution of ALK1 gene dosage or systemic treatment with the ALK1-F-c fusion protein RAP-041 retarded tumor growth and progression by inhibition of angiogenesis in a transgenic mouse model of multistep tumorigenesis. Furthermore, RAP-041 significantly impaired the in vitro and in vivo angiogenic response toward vascular endothelial growth factor A and basic fibroblast growth factor. In seeking the mechanism for the observed effects, we uncovered an unexpected signaling synergy between TGF-beta and BMP9, through which the combined action of the two factors augmented the endothelial cell response to angiogenic stimuli. We delineate a decisive role for signaling by TGF-beta family members in tumor angiogenesis and offer mechanistic insight for the forthcoming clinical development of drugs blocking ALK1 in oncology.Keywords
This publication has 54 references indexed in Scilit:
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant MetastasisCancer Cell, 2009
- Plasminogen Activator Inhibitor-1 Protects Endothelial Cells from FasL-Mediated ApoptosisCancer Cell, 2008
- Transforming Growth Factor-β Requires Its Target Plasminogen Activator Inhibitor-1 for Cytostatic ActivityJournal of Biological Chemistry, 2008
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2Blood, 2008
- BMP7, a Putative Regulator of Epithelial Homeostasis in the Human Prostate, Is a Potent Inhibitor of Prostate Cancer Bone Metastasis in VivoThe American Journal of Pathology, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescenceNature, 2006
- Hereditary hemorrhagic telangiectasia: an update on clinical manifestations and diagnostic measuresWiener klinische Wochenschrift, 2006
- The L45 loop in type I receptors for TGF‐β family members is a critical determinant in specifying Smad isoform activationFEBS Letters, 1998